TrialCell reports. Medicine2025

Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers.

Eric J Jaehnig et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.